Patents by Inventor William H. Parsons

William H. Parsons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170313669
    Abstract: Provided herein are lactone compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as inhibitors of serine hydrolases, such as ABHD16A. Furthermore, the subject compounds and compositions may be useful for the treatment of, for example, PHARC and other neuroinflammatory diseases.
    Type: Application
    Filed: October 27, 2015
    Publication date: November 2, 2017
    Inventors: Benjamin F. CRAVATT, Siddhesh S. KAMAT, William H. PARSONS, Amy R. HOWELL, Kaddy CAMARA, Amy ANDERSON
  • Publication number: 20110190364
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Application
    Filed: April 12, 2011
    Publication date: August 4, 2011
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Wells, Derek A. Beauchamp
  • Publication number: 20110190344
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Application
    Filed: April 12, 2011
    Publication date: August 4, 2011
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Wells, Derek A. Beauchamp
  • Patent number: 7951829
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: May 31, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Wells, Derek A. Beauchamp
  • Patent number: 7888345
    Abstract: Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: February 15, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott B. Hoyt, Clare London, Dong Ok, William H. Parsons
  • Patent number: 7612211
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: November 3, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Wing S. Cheung, Daniel J. Parks, William H. Parsons, Sharmila Patel, Mark R. Player
  • Patent number: 7589116
    Abstract: Biaryl substituted pyrazole compounds are sodium channel blockers useful for the treatment of pain and other conditions. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treatment of conditions, including acute pain, chronic pain, visceral pain, inflammatory pain, and neuropathic pain, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more therapeutically active compounds.
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: September 15, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Prasun K. Chakravarty, Michael H. Fisher, Jeffrey M. Fisher, legal representative, William H. Parsons, Sriram Tyagarajan, Bishan Zhou
  • Patent number: 7572822
    Abstract: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: August 11, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Prasun K. Chakravarty, Louis L. Zuegner, III, legal representative, William H. Parsons, Brenda Palucki, Bishan Zhou, Min K. Park, Michael H. Fisher
  • Publication number: 20090181946
    Abstract: Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Application
    Filed: June 5, 2007
    Publication date: July 16, 2009
    Inventors: Scott B. Hoyt, Clare London, Dong Ok, William H. Parsons
  • Publication number: 20090074890
    Abstract: Substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, migraine, headache pain, migraine headache, epilepsy, irritable bowel syndrome, diabetic neuropathy, multiple sclerosis, manic depression and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Application
    Filed: November 5, 2004
    Publication date: March 19, 2009
    Inventors: Min K. Park, Prasun K. Chakravarty, Bishan Zhou, Edward Gonzalez, Hyun Ok, Brenda Palucki, William H. Parsons, Rosemary Sisco, Michael H. Fisher, Louis L. Zuegner, III
  • Patent number: 7459475
    Abstract: Substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, migraine, headache pain, migraine headache, epilepsy, irritable bowel syndrome, diabetic neuropathy, multiple sclerosis, manic depression and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: December 2, 2008
    Assignee: Merck & Co. Inc.
    Inventors: Min K. Park, Prasun K. Chakravarty, Bishan Zhou, Edward Gonzalez, Hyun Ok, Brenda Palucki, William H. Parsons, Rosemary Sisco, Louis L. Zuegner, III, legal representative, Michael H. Fisher
  • Publication number: 20080280873
    Abstract: Biaryl substituted pyrazinone compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Application
    Filed: March 25, 2005
    Publication date: November 13, 2008
    Inventors: Jun Liang, Prasun K. Chakravarty, Deborah E. Pan, William H. Parsons, Pengcheng P. Shao, Feng Yee, Bishan Zhou
  • Patent number: 7414067
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Grant
    Filed: March 24, 2004
    Date of Patent: August 19, 2008
    Assignees: Merck & Co. Inc., Evotec OAI
    Inventors: Edward Andrew Boyd, Michael H. Fisher, Maria L. Garcia, Gregory J. Kaczorowski, Peter T. Meinke, William H. Parsons, Stephen Price, John Stibbard
  • Publication number: 20080171777
    Abstract: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Application
    Filed: January 30, 2008
    Publication date: July 17, 2008
    Inventors: Prasun K. Chakravarty, Michael H. Fisher, Louis L. Zuegner, William H. Parsons, Brenda Palucki, Bishan Zhou, Min K. Park
  • Publication number: 20080146637
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Application
    Filed: December 12, 2007
    Publication date: June 19, 2008
    Inventors: Wing S. Cheung, Daniel J. Parks, William H. Parsons, Sharmila Patel, Mark R. Player
  • Patent number: 7348348
    Abstract: Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: March 25, 2008
    Assignee: Merck & Co. Inc.
    Inventors: Howard C. H. Kuo, Michelle B. Ayer, Prasun K. Chakravarty, Peter T. Meinke, William H. Parsons, Sriram Tyagarajan
  • Patent number: 7326726
    Abstract: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: February 5, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, Louis L. Zuegner III, legal representative, Brenda Palucki, Min K. Park, William H. Parsons, Bishan Zhou, Michael H. Fisher, deceased
  • Publication number: 20070259936
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Application
    Filed: April 13, 2007
    Publication date: November 8, 2007
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Weils, Derek A. Beauchamp
  • Patent number: 6632836
    Abstract: The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 14, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Jennifer Chee, Maria L. Garcia, Gregory J. Kaczorowski, Frank Kayser, Andrew Kotliar, Chou Juitsai Liu, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht, William A. Schmalhofer, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Patent number: 6545023
    Abstract: The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6 and X are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: April 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Lihu Yang, Gabor Butora, William H. Parsons, Alexander Pasternak